| 2025-12-05 |
详情>>
股本变动：
变动后总股本1072.97万股
变动原因 ▼▲
- 原因：
- Common Stock offered 900,000 shares by the company
|
| 2025-12-04 |
复牌提示：
2025-12-04 10:45:37 停牌，复牌日期 2025-12-04 10:50:37
|
| 2025-11-19 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-4.17美元,归母净利润-2766.6万美元,同比去年增长8.80%
|
| 2025-10-23 |
详情>>
内部人交易：
Iwicki Mark T股份减少154894.00股
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-3.13美元,归母净利润-2010.2万美元,同比去年增长6.00%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-1.41美元,归母净利润-894.7万美元,同比去年增长24.22%
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-10.15美元,归母净利润-3851.1万美元,同比去年增长8.74%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-8.68美元,归母净利润-3033.6万美元,同比去年增长9.64%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-7.32美元,归母净利润-2138.6万美元,同比去年增长14.00%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-4.2美元,归母净利润-1180.7万美元,同比去年增长18.32%
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors, Marjan Farid, M.D., Andrew I. Koven and Gregory D. Perry, nominated by our board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified;
2.The approval of an advisory vote on executive compensation;
3.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.The approval of the issuance of shares of our common stock upon conversion of our Series E Convertible Non-Redeemable Preferred Stock, Series F Convertible Non-Redeemable Preferred Stock and Series G Convertible Non-Redeemable Preferred Stock in accordance with Nasdaq Listing Rule 5635(b);
5.The approval of amendments to our Restated Certificate of Incorporation amending the Certificates of Designations, Preferences and Rights of Series E Convertible Non-Redeemable Preferred Stock, Series F Convertible Non-Redeemable Preferred Stock and Series G Convertible Non-Redeemable Preferred Stock as follows:a.The approval of an amendment to our Restated Certificate of Incorporation amending the Series E Certificate of Designations, Preferences and Rights of Series E Convertible Non-Redeemable Preferred Stock to provide discretion to our board of directors to increase the beneficial ownership limitation;b.The approval of an amendment to our Restated Certificate of Incorporation amending the Series F Certificate of Designations, Preferences and Rights of Series F Convertible Non-Redeemable Preferred Stock to provide discretion to our board of directors to increase the beneficial ownership limitation;c.The approval of an amendment to our Restated Certificate of Incorporation amending the Series G Certificate of Designations, Preferences and Rights of Series G Convertible Non-Redeemable Preferred Stock to provide discretion to our board of directors to increase the beneficial ownership limitation;
6.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-17.35美元,归母净利润-4219.9万美元,同比去年增长5.85%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-14.36美元,归母净利润-3357.2万美元,同比去年增长-4.98%
|
| 2023-08-04 |
详情>>
业绩披露：
2023年中报每股收益-11.15美元,归母净利润-2486.8万美元,同比去年增长59.27%
|
| 2023-05-11 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors, C. Daniel Myers and Howard B. Rosen, nominated by our board of directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his successor has been duly elected and qualified;
2.The approval of an advisory vote on executive compensation;
3.The holding of an advisory vote on the frequency of future executive compensation advisory votes;
4.The approval of the Amended and Restated 2017 Equity Incentive Plan;
5.The approval of an amendment to our Restated Certificate of Incorporation to change our name from “Kala Pharmaceuticals, Inc.” to “Kala Bio, Inc.”;
6.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2023-03-13 |
股东大会：
将于2023-04-24召开股东大会
会议内容 ▼▲
- 1.To approve the one-time exchange of stock options issued under the Company’s 2009 Employee, Director and Consultant Equity Incentive Plan (the “2009 Plan”), the Company’s 2017 Equity Incentive Plan (the “2017 Plan”), and inducement awards granted to certain newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4) (“inducement awards”) that are held by executive officers, other employees, and non-employee directors (collectively, “Eligible Holders”) of the Company for newly issued restricted stock units (the “Option Exchange Proposal”);
2.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 (the “Auditor Ratification Proposal”);
3.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal and the Auditor Ratification Proposal (the “Adjournment Proposal”).
|
| 2022-10-21 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2022-09-09 |
股东大会：
将于2022-10-19召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our restated certificate of incorporation to effect, at the discretion of our Board of Directors (the “Board”) but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of our common stock, par value $0.001 per share (“Common Stock”), at a ratio in the range of 1-for-2 to 1-for-75, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”);
2.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2022-08-11 |
财报披露：
美东时间 2022-08-11 盘前发布财报
|
| 2022-04-29 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.The election of two Class II directors, Mark Iwicki and Mark S. Blumenkranz, M.D., nominated by our board of directors, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders or until his successor has been duly elected and qualified;
2.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.The election of two Class I directors, Andrew I. Koven and Gregory D. Perry, nominated by our board of directors, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders or until his successor has been duly elected and qualified;
2.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2020-06-10 |
股东大会：
将于2020-06-25召开股东大会
会议内容 ▼▲
- 1.The election of three Class III directors, Robert Paull, Howard B. Rosen and Rajeev Shah, nominated by our board of directors, each to serve for a three-year term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified;
2.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.The approval of an amendment to the 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder;
4.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2019-04-12 |
股东大会：
将于2019-06-05召开股东大会
会议内容 ▼▲
- 1.The election of two Class II directors, Mark Iwicki and Gregory Grunberg, nominated by our board of directors, each to serve for a three-year term expiring at the 2022 annual meeting of stockholders or until his successor has been duly elected and qualified;
2.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2018-04-25 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors, Mark T. Iwicki, Andrew I. Koven, and Gregory D. Perry, nominated by our board of directors, each to serve for a three-year term expiring at the 2021 annual meeting of stockholders or until his successor has been duly elected and qualified;
2.The ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|